Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes Clinical Trial

Official title:

A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group to Evaluate the Efficacy and Safety of Cc-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02281084
• Other study ID #: CC-486-MDS-006
• Secondary ID: 2014-002675-29
• Status: Completed
• Phase: Phase 2
• Start date: July 6, 2015
• Est. completion date: September 14, 2023

Study information

• Verified date: February 2024
• Source: Celgene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an objective response post injectable hypomethylating agent (iHMA) treatment

Reason for removing the combination arm: Due to difficulties with dose-finding, the durvalumab plus CC-486 combination arm was closed to enrollment.

Extension:

An Extension Phase (EP) has been added to allow subjects who are currently receiving oral azacitidine BID and who are demonstrating clinical benefit as assessed by the Investigator, to continue receiving oral azacitidine until the subject meets the criteria for study discontinuation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: September 14, 2023
• Est. primary completion date: June 19, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female, = 18 years of age at the time of signing the informed consent document

2. Documented diagnosis of MYELODYSPLASTIC SYNDROMES (MDS), classified according to FRENCH-AMERICAN BRITISH (FAB) classification criteria

3. Adequate course of treatment with an injectable hypomethylating agent (azacitidine for injection or decitabine) as the last therapeutic intervention for MDS prior to beginning screening for this study. Adequate is defined as:

• having received at least 6 consecutive 4-week treatment cycles with azacitidine for injection, or

• having received at least 4 consecutive 6-week treatment cycles with decitabine (3-day regimen) or at least 6 consecutive 4-week treatment cycles with decitabine (5-day regimen), or

• having demonstrated inability to tolerate treatment with an injectable hypomethylating agent because of unacceptable drug-related toxicity after at least 3 months of attempted treatment: Three 28-day cycles of azacitidine for injection or decitabine 5-day regimen; two 42-day cycles of decitabine 3-day regimen.

4. Documented disease progression or stable disease as best response to treatment (or attempted treatment) with azacitidine for injection or decitabine. Those achieving an objective response to treatment regimen with an injectable hypomethylating agent (HMA) are excluded from participation in this study.

Definitions of disease progression are modified from INTERNATIONAL WORKING GROUP (IWG) 2006 criteria and include:

• Pre-injectable hypomethylating agent baseline bone marrow myeloblasts:

1. Less than 5%: = 100% increase to = 8% blasts

2. = 5%: = 50% increase to = 10% blasts Note: = 30% blasts is considered acute myeloid leukemia (AML )per FAB classification. Subjects known to have = 30% blasts are not eligible for inclusion in this study.recognizing eastern cooperative oncology group) limitations of blast cell quantification, Protocol will allow subjects with pre-enrollment bone marrow blast counts up to 33% on the screening bone marrow examination to be considered for inclusion. Assessment may be made according to local bone marrow examination to facilitate enrollment of eligible subjects into the treatment phase of the study.

• Any clinical worsening from pre-injectable hypomethylating agents (HMA) baseline condition, including:

1. sustained clinically-significant worsening (investigator's assessment) from baseline granulocyte, platelet, or hemoglobin values (= 2 values, separated by = 2 weeks) - worsening granulocytes should be = 50% decrease from pre-injectable HMA baseline value - worsening platelets should be = 50% decrease from pre-injectable HMA baseline value (untransfused)

• worsening hemoglobin should be = 1.5 g/dL decrease from preinjectable HMA baseline value in subjects not receiving RBC transfusions

2. meaningful worsening in RBC or platelet transfusion requirement

Definition of stable disease is based on modified IWG 2006 criteria:

• Failure to achieve any objective response (CR - complete remission, PR - partial remissino, mCR - marrow complete remission, or HI - hematologic improvement), but no evidence of disease progression within the 8 weeks leading to the subject's first dose of investigational product (IP), Cycle 1, Day 1

5. Have the last dose of the prior treatment regimen injectable HMA - (azacitidine for injection or decitabine) not more than 16 weeks prior to screening for this study (date of informed consent signature).

6. No less than 3 weeks between the last dose of the prior treatment regimen injectable HMA - (azacitidine for injection or decitabine) and the planned date of first dose of IP (

7. Have an eastern cooperative oncology group (ECOG) performance status of 0, 1, or 2

8. Females subjects of childbearing potential (FCBP)1 may participate, providing they meet the following conditions:

1. Have two negative pregnancy tests as verified by the investigator prior to starting any IP therapy: serum pregnancy test at screening and negative serum or urine pregnancy test (investigator's discretion) within 72 hours prior to starting treatment with IP (Cycle 1, Day 1). They must agree to ongoing pregnancy testing during the course of the study (before beginning each subsequent cycle of treatment), and after the last dose of any IP. This applies even if the subject practices complete abstinence2 from heterosexual contact.

2. Agree to practice true abstinence2 (which must be reviewed on a monthly basis and source documented) or agree to the use of highly effective methods of contraception from 28 days prior to starting azacitidine, and must agree to continue using such precautions while taking azacitidine (including dose interruptions) and for up to 90 days after the last dose of azacitidine. Cessation of contraception after this point should be discussed with a responsible physician

3. Agree to abstain from breastfeeding during study participation and for at least 90 days after the last dose of IP.

Note that the screening serum pregnancy test can also be used as the test prior to starting IP if it is performed within the 72-hour timeframe.

9. Male subjects must:

1. Male subjects must:

1. Either practice true abstinence2 from heterosexual contact (which must be reviewed on a monthly basis) or agree to avoid fathering a child, to use highly effective methods of contraception, male condom plus spermicide during sexual contact with a pregnant female or a female of child bearing potential (even if he has undergone a successful vasectomy) from starting dose of IP (Cycle 1 Day 1), including dose interruptions through 90 days after receipt of the last dose of azacitidine.

2. Refrain from semen or sperm donation while taking IP and for at least 90 days after the last dose of IP.

10. Understand and voluntarily sign an informed consent document prior to any study-related assessments or procedures conducted.

11. Be able to adhere to the study visit schedule and other protocol requirements.

12. Understand and voluntarily sign a biomarker-specific component of the informed consent document prior to any study-related procedures conducted.

Extension Phase

At the Investigator's discretion and following confirmation of eligibility criteria below, subjects can enter the Extension Phase (EP):

• Subjects who have signed the informed consent for the EP of the study;

• Subjects receiving oral azacitidine and continuing in the treatment phase demonstrating clinical benefit as assessed by the Investigator are eligible to receive oral azacitidine in the EP;

• Subjects who do not meet any of the criteria for study discontinuation

Exclusion Criteria:

1. Rapidly-progressing MDS defined as:

1. Known clinically-significant doubling in marrow or per IP peripheral blood blast percentage (to = 20%) in the 8-week period leading to the first dose of IP (Cycle 1, Day 1)

2. =100% increase in WBC count (myeloid cell line and monocyte series) within the 8-week period leading to Cycle 1, Day 1

2. AML - FAB (FRENCH-AMERICAN-BRITISH) classification: = 30% blasts in bone marrow). Subjects known to have = 30% blasts are not eligible for inclusion in this study. Recognizing limitations of blast cell quantification, this protocol will allow subjects with pre-enrollment (screening/baseline) bone marrow blast counts up to 33% to be considered for inclusion.

3. Prior allogeneic stem cell transplant

4. Prior exposure to the investigational oral formulation of decitabine, or other oral azacitidine derivative at any time in the subject's prior history

5. Prior or ongoing response (IWG 2006: HI, PR, CR, or marrow CR) to treatment with azacitidine for injection or decitabine, at any time in the subject's prior history, which includes relapsed disease

6. Ongoing medically significant adverse events from previous treatment, regardless of the time period

7. Use of any of the following within 28 days prior to the first dose of IP:

1. thrombopoiesis-stimulating agents ([TSAs]; eg, Romiplostim, Eltrombopag, Interleukin-11)

2. ESAs (Erythropoiesis stimulating agent) and other RBC hematopoietic growth factors (eg, interleukin-3)

3. hydroxyurea

8. Concurrent use of corticosteroids unless the subject is on a stable or decreasing dose for = 1 week prior to enrollment for medical conditions other than MDS

9. History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the IP and/or predispose the subject to an increased risk of gastrointestinal toxicity

10. Prior history of malignancies, other than MDS, unless the subject has been free of the disease for = 3 years. However, subjects with the following history/concurrent conditions are allowed:

1. Basal or squamous cell carcinoma of the skin

2. Carcinoma in situ of the cervix

3. Carcinoma in situ of the breast

4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system)

11. Significant active cardiac disease within the previous 6 months, including:

1. New York Heart Association (NYHA) class IV congestive heart failure;

2. Unstable angina or angina requiring surgical or medical intervention; and/or

3. Myocardial infarction

12. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)

13. Known Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of active Hepatitis B Virus (HBV) infection

14. Any of the following laboratory abnormalities:

1. Serum Aspartate transaminase / Serum glutamic oxaloacetic transaminase (AST/SGOT) Alanine aminotransaminase / Serum glutamic pyruvate transaminase (ALT/SGPT) > 2.5 x ULN (upper limit of normal)

2. Serum total bilirubin > 1.5 x upper limit of normal (ULN). Higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (ie, ineffective erythropoiesis). Subjects are excluded if there is evidence of autoimmune hemolytic anemia manifested as a corrected reticulocyte count of > 2% with either a positive Coombs' test or over 50% of indirect bilirubin

3. Serum creatinine > 2.5 x ULN (upper limit of normal)

4. Absolute WBC (white blood cell) count = 20 x 109/L

15. Known or suspected hypersensitivity to azacitidine, mannitol, its constituents, or to any other humanized monoclonal antibody

16. Pregnant, planning to become pregnant starting from 28 days prior to receiving CC-486 throughout your participation in the study, and for at least 90 days following your last dose of study treatment, or breast-feeding females

17. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study

18. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study

19. Any condition that confounds the ability to interpret data from the study, including known or suspected conditions other than MDS, associated with anemia

20. Having received any prior MAb (monoclonal antibodies) against CTLA-4 (cytotoxic T lymphocyte-associated antigen), PD-1, or PD-L1 or having received other investigational monoclonalantibodies (MAbs) within 6 months

21. Clinical evidence of central nervous system (CNS) or pulmonary leukostasis, or CNS leukemia

22. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis, Crohn's disease], diverticulitis with the exception of a prior episode that has resolved or diverticulosis, celiac disease, irritable bowel disease, or other serious gastrointestinal chronic conditions associated with diarrhea; systemic lupus erythematosus; Wegener's syndrome [granulomatosis with polyangiitis]; myasthenia gravis; Graves' disease; rheumatoid arthritis; hypophysitis, uveitis; etc) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:

1. Subjects with vitiligo or alopecia;

2. Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement for = 3 months; or

3. Subjects with psoriasis not requiring systemic treatment

23. History of primary immunodeficiency

24. Active myeloproliferative neoplasms (MPN) and chronic myelomonocytic leukemia (CMML)

Related Conditions & MeSH terms

• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• Oral Azacitidine
Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
• Durvalumab
Durvalumab 1500 mg by IV infusion on Day 1 of each 28 day treatment cycle.

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital	Adelaide	South Australia
Australia	Local Institution - 400	Clayton	Victoria
Australia	Monash Medical Centre	Clayton	Victoria
Australia	Royal Brisbane and Women's Hospital	Herston
Australia	Cabrini Hospital	Malvern	Victoria
Australia	Local Institution - 405	Malvern	Victoria
Australia	Royal Perth Hospital	Perth
Australia	Westmead Hospital	Westmead	New South Wales
Belgium	Local Institution - 801	Brussel
Belgium	Universitair Ziekenhuis Brussel	Brussel
Belgium	Hopital Erasme	Bruxelles
Belgium	Centre Hospitalier Universitaire de Liege	Liège
Belgium	Clinique Saint-Pierre	Ottignies
Canada	Local Institution - UNK-004	Hamilton	Ontario
France	Institut Paoli Calmettes	Marseille Cedex 9
France	Hopital Saint-Louis	Paris
France	Local Institution - 201	Paris
France	CHU Purpan	Toulouse
Germany	Local Institution - 500	Dresden
Germany	Universitatsklinikum Carl Gustav Carus an der TU Dresden	Dresden
Germany	Local Institution - 502	Dusseldorf
Germany	Marien Hospital	Dusseldorf
Germany	Universitatsklinikum Freiburg	Freiburg
Germany	Universitatsklinikum Halle Saale	Halle
Germany	Universitatsklinikum Leipzig	Leipzig
Germany	Medizinische Klinik III Klinikum der Universität München-Großhadern	München
Italy	Azienda Ospedaliera Santi Antonio Biagio E Cesare Arrigo	Allessandria
Italy	Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi	Bologna
Italy	Azienda Ospedaliero-Universitaria Careggi	Firenze
Italy	Local Institution - 601	Firenze
Italy	Ospedale San Raffaele S.r.l.	Milano
Italy	Azienda Ospedaliera Sant Andrea	Roma
Italy	Local Institution - 603	Roma
Poland	Zaklad Opieki Zdrowotnej MSW z Warminsko-Mazurskim Centrum Onkologii	Olsztyn
Poland	MTZ Clinical Research Sp. z o.o.	Warszawa
Poland	Uniwersytecki Szpital Kliniczny	Wroclaw
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Institut Calatà d'Oncologia, L'Hospitalet	Barcelona
Spain	Local Institution - 306	Barcelona
Spain	Hospital Virgenes de las Nieves	Granada
Spain	Hospital General Gregorio Maranon	Madrid
Spain	Hospital Universitario Virgen De La Victoria	Malaga
Spain	Hospital Central de Asturias	Oviedo
Spain	Hospital Universitario de Salamanca	Salamanca
Spain	Hospital Universitario Virgen Del Rocio	Sevilla
Spain	CEIC Hospital Universitario La Fe	Valencia
United Kingdom	United Lincolnshire Hospitals NHS Trust	Boston
United Kingdom	Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital	Cambridge
United Kingdom	Broomfield Hospital	Chelmsford
United Kingdom	Saint James University Hospital	Leeds
United Kingdom	Hammersmith Hospital	London
United Kingdom	King's College HospitalSchool of Medicine	London
United Kingdom	Local Institution - 700	London
United Kingdom	University College London	London
United Kingdom	Northwick Park Hospital	Middlesex
United Kingdom	Southampton General Hospital	Southampton
United States	University of Chicago Medicine	Chicago	Illinois
United States	John Theurer Cancer Center at Hackensack University Medical Center	Hackensack	New Jersey
United States	Ingalls Memorial Hospital	Harvey	Illinois
United States	University of Texas- MD Anderson	Houston	Texas
United States	University of Iowa Hospitals and Clinics	Iowa City	Iowa
United States	James Graham Brown Cancer Center	Louisville	Kentucky
United States	University of Miami Miller School of Medicine	Miami	Florida
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Local Institution - 113	New Haven	Connecticut
United States	Yale University	New Haven	Connecticut
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	Local Institution - 101	New York	New York
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Hillman Cancer Institute at UPMC	Pittsburgh	Pennsylvania
United States	Cancer Care Centers of South Texas - HOAST	San Antonio	Texas
United States	H Lee Moffitt Cancer Center and Research Institute	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Celgene

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Canada,  France,  Germany,  Italy,  Poland,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate Based on the Modified International Working Group (IWG) 2006 Response Criteria for Myelodysplastic Syndrome (MDS)	The overall response rate (ORR) was defined as the percentage of participants who achieved an objective response including: hematologic improvement (HI), partial remission (PR), complete remission (CR), or marrow complete remission (mCR). Hematologic response was defined as: CR: = 5% myeloblasts with normal maturation of all cell lines; peripheral blood (PB) shows: hemoglobin =11 g/dL, neutrophils =1.0x10^9/L, platelets =100x10^9/dL, blasts (0%); PR: same as CR bone marrow (BM) shows blasts decreased by = 50% over pre-treatment but still > 5%; cellularity and morphology not relevant; mCR: BM: = 5% myeloblasts and decrease by = 50% over pre-treatment PB, PB: if HI responses, noted in addition to mCR; HI: HI erythroid response (HI-E); HI neutrophil response (HI-N) ; HI platelet response (HI-P)	Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Secondary	Kaplan-Meier Estimate of Overall Survival	Overall survival (OS) was defined as the time from randomization to death from any cause, and was calculated using date of first dose and date of death, or date of last follow-up for censored subjects. All participants were followed until drop out (withdrawal of consent from further data collection or lost to follow-up), death, or study termination. Participants who dropped out or were alive at study termination (or at the time of the interim analysis) had their OS times censored at the time of last contact, as appropriate.	From day 1 of study drug to the data cut off date of 19 June 2019; median follow-up for OS = 15.96 and 8.35 months respectively in the SD and PD oral AZA alone arms and 13.48 and 13.33 months in the SD and PD combination arms
Secondary	Kaplan Meier Estimate of Time to Onset of First and Best Response	Time to onset of first response was defined as the time between the date of first investigational product (IP) dose and the earliest date any response (CR, PR, mCR, or HI) was first observed. Participants who did not achieve any defined response during the treatment period were censored at the date of treatment discontinuation, disease progression, or death, whichever occurred first. Best response is the best recorded response or treatment outcome from the start of the study treatment until the end of the study treatment taking into account the requirements for confirmation of response.	Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Secondary	Kaplan Meier Estimate of Duration of First Response	Duration of hematologic response and/or improvement was defined as the time from the date response or improvement was first observed to the date of documented relapse or disease progression as defined by the modified IWG 2006 criteria. Particpants who maintained hematologic response and/or improvement through the end of the treatment period were censored as the date of treatment discontinuation or death, whichever occurred first.	Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Secondary	Kaplan Meier Estimate of Duration of Best Response	Duration of hematologic response and/or improvement was defined as the time from the date response or improvement was first observed to the date of documented relapse or disease progression as defined by the modified IWG 2006 criteria. Particpants who maintained hematologic response and/or improvement through the end of the treatment period were censored as the date of treatment discontinuation or death, whichever occurred first.	Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Secondary	Kaplan-Meier Estimate of Progression Free Survival (PFS)	Progression-free survival is defined as the time from randomization to the first documented progressive disease (PD), relapse, or death due to any cause during or after the treatment period, whichever occurred first, according to IWG 2006 response criteria for MDS. Participants who were still alive and progression-free were censored at the date of their last response assessment. Progressive disease is defined as follows: - an increase in BM blasts relative to nadir: •If nadir less than 5% blasts: = 50% increase in blasts to > 5% blasts •If nadir 5% - 10% blasts: = 50% increase in blasts to > 10% blasts •If nadir 10% - 20% blasts: = 50% increase in blasts to > 20% blasts •If nadir 20% - 30% blasts: = 50% increase in blasts to > 30% blasts And any of the following: •At least 50% decrement from maximum remission/response levels in granulocytes or platelets •Reduction in Hgb concentration by = 2 g/dL •Transfusion dependence	From day 1 of study drug to the data cut off date of 19 June 2019; median follow-up for OS = 15.96 and 8.35 months respectively in the SD/ PD oral AZA arms and 13.48 and 13.33 months in the SD/PD oral AZA and Durva arms
Secondary	Percentage of Participants With Progressive Disease at Baseline Who Achieved Stable Disease	A participant was considered as having a stable disease if the disease neither responded nor progressed during or after study treatment.	Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Secondary	Kaplan-Meier Estimate of Onset to Achieve Stable Disease	A participant was considered as having a stable disease if the disease neither responded nor progressed during or after study treatment.	Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Secondary	Kaplan-Meier Estimate of Duration of Stable Disease	The duration of stable disease was defined as the time between any two observations of objective disease progression (modified IWG criteria), starting from the first day of dosing with IP. Participants who maintained stable disease through the end of the treatment period were censored at the date of study termination.	Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms
Secondary	Percentage of Participants Who Progressed to Acute Myelogenous Leukemia (AML)	For all participants who received at least one dose of study drug, continuous monitoring for progression to AML occurred in the post treatment follow up period.	From Day 1 of study drug up to the data cut off date of 19 June 2019; median follow up time for AML progression = 11.59 and 5.65 months respectively in the SD and PD arms for oral AZA and 6.21 months for SD/PD in the combination arm.
Secondary	Kaplan-Meier Estimate of Time to Progression to AML	Time to AML progression was defined as the time from the date of first dose of IP until the date the participant had documented progression to AML.	From Day 1 of study drug up to the data cut off date of 19 June 2019; median follow up time for AML progression = 11.59 and 5.65 months respectively in the SD and PD arms for oral AZA and 6.21 months for SD/PD in the combination arm.
Secondary	Number of Participants With Treatment Emergent Adverse Events (TEAEs)	TEAEs were defined as AEs occurring or worsening on or after the date of the first dose of oral aza or durva and within 28 days after last dose of oral aza or 90 days after last dose of durva; A serious adverse event (SAE) is any: Death; Life-threatening event; Any inpatient hospitalization or prolongation of existing hospitalization; Persistent or significant disability or incapacity; Congenital anomaly or birth defect; Any other important medical event The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death.	From first dose of IP until 28 days after final oral AZA dose, 90 days after final durva dose and/or treatment stopped; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively; 1.84 months for AZA and Durva SD/PD arms

External Links

•   BMS Clinical Trial Information